whitePaper

White paper

The NDC-12 Cross-Industry Pilot: Implications & Findings for the Physical Supply Chain

Read the white paper
Pharmaceutical specialist reviews medicine inventory for NDC-12 impact analysis, system updates, and supply chain compliance.

NDC-12 Pilot Phase "1"—A continuation of the work done in Phase "0"

The transition to a uniform 12-digit National Drug Code (NDC) will reach far beyond regulatory compliance, affecting master data, product labeling, technology platforms, financial processes, and physical supply-chain operations across the pharmaceutical ecosystem. Drawing on NNIT’s cross-industry pilot, this white paper explores the practical complexities organizations may face as NDC-10 and NDC-12 products and data coexist.

In this free white paper, discover the pilot’s key findings, high-risk areas, and real-world considerations for artwork, barcodes, electronic transactions, inventory, financial settlement, and trading-partner coordination. Discover why organizations should begin assessing their processes, systems, vendors, and dependencies now to build a realistic and coordinated transformation roadmap.

This white paper discusses:

  • How NDC-12 will affect operations across the pharmaceutical ecosystem

  • Where master data, labeling, barcodes, systems, and trading-partner transactions create the greatest risks

  • Practical insights from cross-industry workshops and physical supply-chain simulations

  • Why organizations should begin their NDC-12 impact assessments and transition planning now

Start your NDC-12 Journey

If your organization is preparing for the 12-digit NDC format and needs guidance on impact analysis, system updates, or transition planning, our team can help.

When you submit your inquiry to NNIT via the contact form, NNIT process the collected personal data in accordance with the Privacy Notice, where you can read more about your rights and how NNIT process your personal data.